/LIPO
LIPO Stock - Lipella Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$0.21+2.38%
+$0.01 (+2.38%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+830.2%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LIPO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.21 – $0.22
TARGET (TP)$2.00
STOP LOSS$0.20
RISK/REWARD1:119.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.01
52W High$7.31
52W Low$0.21
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $536,357 | $449,617 | $184,156 | $259,347 | $961,683 |
| Gross Profit | $-3,076,830 | $-2,589,219 | $-2,363,521 | $-1,197,444 | $-14,277 |
| Gross Margin | -573.7% | -575.9% | -1283.4% | -461.7% | -1.5% |
| Operating Income | $-5,080,542 | $-4,745,953 | $-2,589,713 | $-1,915,828 | $-56,862 |
| Net Income | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 | $-61,656 |
| Net Margin | -935.2% | -1027.3% | -1410.6% | -719.3% | -6.4% |
| EPS | $-4.79 | $-6.16 | $-5.12 | $-4.00 | $-0.23 |
Company Overview
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LIPOBeat Rate
25%
Last 4 quarters
Avg Surprise
+4.2%
EPS vs Estimate
Beats / Misses
1/1
2 met exactly
Latest EPS
$-0.28
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
0.0%
$-1.28vs$-1.28
Q3 24
0.0%
$-0.96vs$-0.96
Q4 24
-34.4%
$-1.29vs$-0.96
Q1 25
+51.0%
$-1.19vs$-2.43
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.28 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.31 | — | — |
Q2 2025 | May 14, 2025 | — | $-0.64 | — | — |
Q1 2025 | Mar 27, 2025 | $-2.43 | $-1.19 | +51.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.96 | $-1.29 | -34.4% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.96 | $-0.96 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $-1.28 | $-1.28 | 0.0% | = MET |
Q1 2024 | Feb 27, 2024 | — | $-0.72 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-1.84 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-2.16 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-1.49 | — | — |
Q2 2023 | May 15, 2023 | — | $-1.52 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-1.39 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.62 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.53 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.79 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-1.09 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.80 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-1.95 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LIPO
What is LIPO's current stock price?
Lipella Pharmaceuticals Inc. (LIPO) is currently trading at $0.21 per share. The stock has moved +2.38% today.
What is the analyst price target for LIPO?
The average analyst price target for LIPO is $2.00, based on 1 analyst.
What sector is Lipella Pharmaceuticals Inc. in?
Lipella Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LIPO's market cap?
Lipella Pharmaceuticals Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does LIPO pay dividends?
No, Lipella Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
AZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
Explore stocks similar to LIPO for comparison